A Phase 3 interventional study of furmonertinib 240 mg oral, daily and furmonertinib 160 mg oral, daily in Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer and EGFR Exon 20 Mutations, sponsored by ArriVent BioPharma, Inc.. Active, not recruiting at 208 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by ArriVent BioPharma, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.
Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, reaches primary completion later than 13 of the 33 other live ones, and was the 14th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Peking University Cancer Hospital & Institute · Sites in China
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–75
Hunan Cancer Hospital · Sites in China
Ages 18+
Guangzhou University of Traditional Chinese Medicine · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 30 · Phase 3 5
First in 2017; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 398 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 60 across the 41 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 41 have an industry lead sponsor. The 10 most frequent:
ArriVent BioPharma, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
ArriVent BioPharma, Inc. has 3 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
8 of the studies testing aflutinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04853342Phase 3Allist Pharmaceuticals, Inc.To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | 2026-12 |
| NCT06674343Phase 3Peking Union Medical College HospitalFurmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | 2026-12-31 |
| NCT06652048Jialei WangHigh-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | 2026-12 |
| NCT06890182Tianjin Medical University Cancer Institute and HospitalFirmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | 2026-12 |
| NCT06192849Juan LI, MDTo Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | 2026-12-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.
Key Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: furmonertinib 240 mg oral, daily
Drug: furmonertinib 160 mg oral, daily
carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously
Drug: platinum-based chemotherapy
furmonertinib tablet
Also known as: AST2818
furmonertinib tablet
Also known as: AST2818
(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Progression Free Survival (PFS) determined by blinded independent central review (BICR)
Time frame: Up to 32 months after first dose
Overall Survival (OS)
Time frame: Up to 62 months after first dose
PFS determined by investigator assessment
Time frame: Up to 36 months after first dose
Overall response rate (ORR)
Time frame: Up to 36 months after first dose
Duration of response (DOR)
Time frame: Up to 36 months after first dose
Time to second Progression Free Survival (PFS2)
Time frame: Up to 36 months after first dose
PFS by blinded independent central review (BICR) in patients with a history or presence of brain metastases at baseline
Time frame: Up to 36 months after first dose
Time to central nervous system (CNS) metastases by BICR
Time frame: Randomization up to ≤30 days after last dose
CNS ORR evaluated by BICR
Time frame: Randomization up to ≤30 days after last dose
CNS DOR evaluated by BICR
Time frame: Randomization up to ≤30 days after last dose
CNS PFS evaluated by BICR
Time frame: Randomization up to ≤30 days after last dose
Change in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30)
QLQ-C30 is a cancer-specific questionnaire comprised of 5 functional scales (physical, role, cognitive, emotional, and social functioning); 3 symptom scales (fatigue, pain, and nausea/vomiting); and a global health status/quality-of-life (QoL) scale. Six single-item scales are also included (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
Time frame: Randomization up to ≤30 days after last dose
Change in EORTC QLQ Lung Cancer Module Core 13 (QLQ LC13)
QLQ-LC13 is a cancer-specific questionnaire which comprises of 13 questions assessing lung cancer-associated symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and use of pain medication.
Time frame: Randomization up to ≤30 days after last dose
Change in Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC SAQ)
NSCLC-SAQ consists of 7 items assessing 5 NSCLC symptom concepts: cough, pain, dyspnea, fatigue, and poor appetite.
Time frame: Randomization up to ≤30 days after last dose
Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib
Time frame: Up to 36 months after first dose
Plasma concentrations of furmonertinib and its major metabolite (AST5902)
Time frame: Up to 36 months after first dose
Showing the first 100 of 208 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Oct 2026, 40 months.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 40 months is close to that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2025 → Oct 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflutinib
Carcinoma, Non-Small-Cell Lung →
ArriVent BioPharma, Inc.